Showing 261 results

Filters Content type: News, Editors' picks Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

Is Kenya’s lenacapavir rollout missing young women and girls?

Editor's pick
Devex (requires free registration)
22 June 2026
Injectable & long-acting PrEP

MSF launches global campaign demanding Gilead supply HIV prevention drug for $40 a year, everywhere

Editor's pick
MSF
22 June 2026
Injectable & long-acting PrEP

All you need to know about the jab that could dramatically reduce new HIV infections in South Africa

Editor's pick
Spotlight
6 June 2026
Injectable & long-acting PrEP

South Africa Helped Create Lenacapavir, Gilead Should Not Decide Who Gets It

Editor's pick
African Alliance
6 June 2026
Injectable & long-acting PrEP

Lenacapavir (Yeytuo) injected every six months approved for HIV prevention in Canada

Editor's pick
CATIE
6 June 2026
Injectable & long-acting PrEP

How Well Is Lenacapavir PrEP Working in the Real World? It’s Complicated.

Editor's pick
TheBodyPro
6 June 2026
Heterosexual men

HIV in South Africa: why rolling out a groundbreaking new shot will miss a critical group of men

Editor's pick
The Conversation
2 June 2026
Injectable & long-acting PrEP

Injectable PrEP in Leeds and London: criteria, approval and continuation

News
29 May 2026
Injectable & long-acting PrEP

A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It?

Editor's pick
The New York Times (requires free registration)
28 May 2026
Injectable & long-acting PrEP

Misinformation is coming for the anti-HIV jab. Let’s get ahead of it

Editor's pick
Bhekisisa
25 May 2026
Injectable & long-acting PrEP

Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'

Editor's pick
FiercePharma
11 May 2026
Injectable & long-acting PrEP

Who controls South Africa’s lenacapavir rollout? Not South Africa

Editor's pick
Health-E News
24 April 2026
Injectable & long-acting PrEP

Only three new HIV cases on lenacapavir PrEP: updates from PURPOSE-1 and -2

Editor's pick
i-Base
23 April 2026
Injectable & long-acting PrEP

One Million More People to Get HIV ‘Miracle’ Drug Lenacapavir as US, Global Fund Expand Access

Editor's pick
Health Policy Watch
15 April 2026
Injectable & long-acting PrEP

In Eswatini, an HIV Breakthrough Delivered

Editor's pick
The Global Fund
8 April 2026
Injectable & long-acting PrEP

Zimbabwe's new HIV drug lenacapavir at risk as US funding retreats

Editor's pick
SciDev.Net
7 April 2026
Injectable & long-acting PrEP

‘No more than a drop in the ocean’: this drug could end new HIV infections in Eswatini – why isn’t there enough?

Editor's pick
The Guardian
2 April 2026
Injectable & long-acting PrEP

Gilead refuses to sell groundbreaking HIV prevention drug to MSF

Editor's pick
Médecins Sans Frontières
31 March 2026
Injectable & long-acting PrEP

Solving the PrEP Access Problem, One Subscription at a Time

Editor's pick
TheBodyPro
30 March 2026
Injectable & long-acting PrEP

The Launch of Lenacapavir in Zambia

Editor's pick
AVAC
25 March 2026
Injectable & long-acting PrEP

CAB-LA: The prevention jab that never had its moment, and what it leaves behind as LEN arrives

Editor's pick
Bhekisisa
16 March 2026
Injectable & long-acting PrEP

South Africa launches bid to enable local production of long-acting HIV prevention drug, lenacapavir

Editor's pick
Unitaid
7 March 2026
Injectable & long-acting PrEP

Islatravir PrEP didn’t protect against M184V mutation in macaque study

Editor's pick
i-Base
1 March 2026
Injectable & long-acting PrEP

New research: High prevention efficacy and “breakthrough infections” on lenacapavir for PrEP

Editor's pick
San Francisco AIDS Foundation
1 March 2026